You are here

P&T® Journal contents for December 2002

Features

Dr. Goldenberg discusses new drugs that have been approved for the treatment of hepatic disease, hypertension, and type 2 diabetes.
Marvin M. Goldenberg, PhD
The authors review the status of resources and requirements at 85 academic health centers in the U.S.
Alan H. Mutnick, PharmD, John A. Armitstead, MS, Thomas W. Cooley, BS, Kenneth Rockwell, Jr., PharmD, MS, and Karl A. Matuszewski, MS, PharmD

Departments

Editorial
Editor-in-Chief David Nash examines Robert Kegan’s take on why people find it difficult to change.
David B. Nash, MD, MBA
Medication Errors
Drug-related adverse events can be reduced when computerized pharmacy system alerts are fine-tuned on a regular basis.
Matthew Grissinger
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Prescription Washington
Mr. Barlas addresses the government’s interest in accelerating the availability of generic drugs.
Stephen Barlas
Drug Forecast
The authors review a new agent, olmesartan medoxomil, for the treatment of hypertension.
Daryl Norwood, PharmD, Evans Branch III, PharmD, Bridget Smith, MD, and Marlon Honeywell, PharmD